{
    "id": 26423,
    "fullName": "ABL1 P223S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 P223S does not lie within any known functional domains of the Abl1 protein (UniProt.org). P223S has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "P223S",
    "createDate": "04/20/2017",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 119203,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130862880C>T",
        "cDna": "c.667C>T",
        "protein": "p.P223S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10593,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 P223S in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture and in cell line xenograft models (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27640,
            "profileName": "ABL1 P223S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27641,
            "profileName": "BCR - ABL1 ABL1 P223S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119203,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130862880C>T",
            "cDna": "c.667C>T",
            "protein": "p.P223S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}